Prognostic role of PET/CT in endometrial cancer
Abstract
Objectives: The present study evaluates the prognostic value of metabolic parameters related to the primary tumor identified in preoperative fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) scans in patients with endometrial cancer (EC).
Material and methods: This study included 120 patients with EC who underwent PET/CT in the preoperative period. The patients’ age, maximum standardized uptake value (SUVmax), SUVmean, metabolic tumor volume (MTV) and the total lesion glycolysis (TLG) value of the primary tumor on PET/CT; as well as the stage, histological subtype, grade and size of the primary EC; the degree of myometrial invasion (MI) cervical invasion (CI), lymphovascular invasion (LVI), lymph node metastasis (LNM) and distant metastasis (DM) were all recorded. The relationship of these factors with progression-free survival (PFS) and overall survival (OS) was evaluated.
Results: The study included 120 patients with EC with a mean age of 62.3 ± 0.02 years. Of the total, 32 patients died around the time of the analysis and 38 patients showed disease progression. The mean OS was 32.7 ± 1.6 months and the mean PFS was 30.5 ± 2.8 months. No significant relationship was identified between the SUVmax, SUVmean, MTV, TLG values, patient age, tumor size, histology, grade and MI degree, and OS or PFS. Disease stage, LVI, CI, LNM and DM were identified as prognostic factors for OS and PFS.
Conclusions: The present study found no significant relationship between preoperative PET parameters in EC and OS and PFS, although prospective studies involving a larger number of patients are required.
Keywords: endometrial cancersurvivalFDG PET/CTSUVmaxMTVTLG
References
- Kitajima K, Kita M, Suzuki K, et al. Prognostic significance of SUVmax (maximum standardized uptake value) measured by [¹⁸F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging. 2012; 39(5): 840–845.
- Kwon JS. Improving survival after endometrial cancer: the big picture. J Gynecol Oncol. 2015; 26(3): 227–231.
- Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. Obstet Gynecol. 2010; 116(5): 1141–1149.
- Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and Management of Endometrial Cancer. Am Fam Physician. 2016; 93(6): 468–474.
- Kim HJ, Choi J, Jeong YH, et al. Prognostic Value of Metabolic Activity Measured by (18)F-FDG PET/CT in Patients with Advanced Endometrial Cancer. Nucl Med Mol Imaging. 2013; 47(4): 257–262.
- Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95 Suppl 1: S105–S143.
- Shim SH, Kim DY, Lee DY, et al. Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F-FDG PET/CT, predict the recurrence of endometrial cancer. BJOG. 2014; 121(9): 1097–1106; discussion 1106.
- Walentowicz-Sadlecka M, Malkowski B, Walentowicz P, et al. The preoperative maximum standardized uptake value measured by 18F-FDG PET/CT as an independent prognostic factor of overall survival in endometrial cancer patients. Biomed Res Int. 2014; 2014: 234813.
- Berghmans T, Dusart M, Paesmans M, et al. European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2008; 3(1): 6–12.
- Pan L, Gu P, Huang G, et al. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009; 21(9): 1008–1015.
- Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. Groupe d'étude des lymphomes de l'adulte (GELA). SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011; 118(1): 37–43.
- Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med. 2009; 50(4): 527–533.
- Scott AM, Gunawardana DH, Wong J, et al. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009; 36(3): 347–353.
- Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010; 37(1): 181–200.
- Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(1): 16–41.
- Maldonado A, González-Alenda FJ, Alonso M, et al. PET-CT in clinical oncology. Clin Transl Oncol. 2007; 9(8): 494–505.
- NCCN Practice Guidelines Narrative Summary of Indications for FDG PET and PET/ CT. 2/14/2016 ed2016.
- Özgü E, Öz M, Yıldız Y, et al. Prognostic value of 18F-FDG PET/CT for identifying high- and low-risk endometrial cancer patients. Ginekol Pol. 2016; 87(7): 493–497.
- Bollineni VR, Ytre-Hauge S, Bollineni-Balabay O, et al. High Diagnostic Value of 18F-FDG PET/CT in Endometrial Cancer: Systematic Review and Meta-Analysis of the Literature. J Nucl Med. 2016; 57(6): 879–885.
- Liu FY, Chao A, Lai CH, et al. Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma. Gynecol Oncol. 2012; 125(3): 566–571.
- Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010; 118(1): 14–18.
- AlHilli MM, Mariani A, Bakkum-Gamez JN, et al. Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol. 2014; 133(3): 485–493.
